Progress toward predictive models for the outcome of treatment for acute nonlymphocytic leukemia.
A prognostic factor model for "high risk" patients (those more than 70 years old or with secondary leukemia) which involves the serum albumin and platelet count has recently been reported. This model permits the division of the "high risk" patient group into those with an 80% likelihood of surviving high-dose cytosine arabinoside therapy and those with a greater than 70% likelihood of dying.